

2015-2019 Growth Strategies for the Italian Hospital Tumor Marker Testing Market

https://marketpublishers.com/r/293EBA63CD6EN.html

Date: July 2015 Pages: 525 Price: US\$ 3,080.00 (Single User License) ID: 293EBA63CD6EN

Abstracts

This new report from VPGMarketResearch.com contains 525 pages, 38 tables, and presents a comprehensive analysis of the Italian hospital tumor marker testing market, including:

Major issues pertaining to the Italian hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.

Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Test volume and sales forecasts for 40 tumor markers performed in Italian hospitals.

Current instrumentation technologies and feature comparison of leading analyzers.

Sales and market shares of leading suppliers.

Emerging diagnostic technologies and their potential market applications.



Product development opportunities.

Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 525 pages and 38 tables



Contents

INTRODUCTION

WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

- A. Cancer Statistics and Etiology
 - 1. Brest Cancer
 - 2. Lung Cancer
 - 3. Colon and Rectum Cancer
 - 4. Prostate Cancer
 - 5. Stomach Cancer
 - 6. Leukemia
 - 7. Lymphoma
 - 8. Oral Cancer
 - 9. Skin Cancer
 - 10. Uterine Cancer
 - 11. Ovarian Cancer
 - 12. Bladder Cancer
- B. Major Current And Emerging Cancer Diagnostic Tests
 - 1. Introduction
 - 2. Tumor Marker Classification
 - 3. ACTH
 - 4. Alpha-Fetoprotein (AFP)
 - 5. Beta-2 Microglobulin
 - 6. CA 15-3/27.29
 - 7. CA 19-9
 - 8. CA-125
 - 9. Calcitonin
 - 10. Carcinoembrionic Antigen (CEA)
 - 11. Estrogen and Progesterone Receptors
 - 12. Ferritin
 - 13. Gastrin
 - 14. Human Chorionic Gonadotropin (HCG)
 - 15. Insulin
 - 16. NSE
 - 17. Occult Blood
 - 18. PAP Smear/HPV
 - 19. Prostatic Acid Phosphatase (PAP)



- 20. Prostate-Specific Antigen (PSA)
- 21. Squamous Cell Carcinoma Antigen (SCC)
- 22. T and B Lymphocytes
- 23. TdT
- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Tumor Markers
 - ADA
- **B-Protein**
- PNP
- 5'-Nucleotidase
- 27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
- 310
- 28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR



Nerve Growth Factor (NGF) Epidermal Growth Factor (EGF) **Ornithine Decarboxylase** Transferrin Transforming Growth Factor-Alpha 29. Ectopic Hormones 30. Colony Stimulating Factors 31. Lymphokines Alpha-Interferon **B Cell Growth Factors B** Cell Growth Factor (BCGF) Gamma-Interferon Interleukin-1 (IL-1) Macrophage Activating Factor 32. Immunohistochemical Stains 33. Emerging Tumor Markers N-Acetylglucosamine Actin Alpha-Actin **Antineuronal Antibodies** 7B2 B72.3 Bax BCD-F9 BLCA-4 Blood Group Antigens A,B,H CA CA 72-4/TAG-72 CA CA-242 CA-549 CAM CAR-3 Cathepsin-D Chromogranin A and B Cluster 1 Antigen Cluster-5/5A Antigen CTA

CU18



DR-70 DU-PAN-2 **Endometrial Bleeding Associated Factor** Endostatin **Epithelial Membrane Antigen** Feulgen Hydrolysis Fibronectin FSH (1->3)-L-fucosyltransferase Gastrin-Releasing Peptide (GRP) GDCFP-15 Glucagon Glycoamines H23 Her-2 Human Carcinoma Antigen **HPA** HSP27 Intermediate Filaments Cytokeratins/CK18/Cyfra 21-1 Desmin **Gliofibrillary Acid Protein Neurofilaments** Vimentin KA **Kinases KP16D3** LAI Leukocyte Common Antigen Lewis Antigens Lysophosphatidic Acid (LPA) Ma 695/Ma MABDF3 MAG ME1 Minactivin MN/CA9 MSA Mucin Cancer Antigen (MCA)



Multiple Tumor Suppressor Myosin **NEA-130** NMP22 OA-519 **Opiod Peptides** P-glycoprotein Pancreatic Oncofetal Antigen (POA) **Placental Lactogen PR92** Proliferative Index, Ki-67 Px **RB** Inactivation/Deletion Ret SCCL Selectin Sialic Acid Sialyl SSEA-1/SLX **SN10** Somatostatin **TA-90** TABA Tachykinin TAG TPS Troponin Tubulin VCAM VEGF Villen C. Instrumentation Review And Market Needs 1. Abbott AxSYM

- 2. Abbott Architect c4000
- 3. Abbott Architect i2000 Series
- 4. Abbott Architect ci8200 System
- 5. Beckman Coulter UniCel Series
- 6. Beckman Coulter Access
- 7. Binding Site ESP600
- 8. bioMerieux Mini Vidas



- 9. Carolina Chemistries BioLis 24i
- 10. DiaSorin Liaison
- 11. Horiba ABX Pentra
- 12. Inverness DS2
- 13. J&J Vitros ECi/ECiQ
- 14. J&J Vitros 3600
- 15. J&J Vitros 5600
- 16. Olympus AU5400
- 17. Olympus AU3000i
- 18. Olympus AU2700
- 19. Roche Modular Analytics
- 20. Roche Cobas Integra
- 21. Roche Cobas Integra 400 Plus
- 22. Roche Elecsys
- 23. Roche Cobas c311
- 24. Siemens ADVIA Centaur
- 25. Siemens Dimension
- 26. Siemens Dimension RxL Max
- 27. Siemens Dimension Vista
- 28. Siemens Immulite
- 29. Siemens Stratus
- 30. Tosoh AIA-Series
- 31. Vital Diagnostics ATAC 8000
- 32. Vital Diagnostics Envoy
- D. Current and Emerging Technologies
 - 1. Monoclonal and Polyclonal Antibodies
 - 2. Immunoassays
 - a. Technological Principle
 - b. Radioimmunoassay (RIA)
 - c. Enzyme Immunoassays (EIA)
 - Overview

ELISA

- Immunofiltration
- Particle-Membrane Capture Immunoassay
- **Enzyme Amplification**
- d. Fluorescent Immunoassays
- e. Luminescence
- Chemiluminescence
- Bioluminescence



- f. Latex Agglutination
- g. Immunoprecipitation
- h. Affinity Chromatographu
- i. Liposome Flow-Injection Immunoassay
- 3. Molecular Diagnostics
- a. Technology Overview
- b. Amplification Methods
- PCR
- DAP-PCR
- Immuno-PCR
- QC-PCR
- CAR
- DNA
- HPA
- LCR
- NASBA
- QBR
- SDA
- 3 SR, and others
- 4. Chromosome Analysis
- a. Chronic Myelogenous Leukemia (CML)
- b. Acute Myeloid Leukemia (AML)
- c. Acute Lymphoblastic Leukemia (ALL)
- d. Malignant Lymphomas Lymphoid Malignancies
- e. Chronic Lymphocytic Leukemia (CLL)
- f. Solid Cancers
- g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies
- a. CT
- b. MRI
- c. NMR
- d. PET
- e. Photonics Spectroscopy
- E. Personal Testing



ITALY

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers

MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- **D.** Auxiliary Products

DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
 - 1. Marketing Approaches
 - 2. Product Complexity
 - 3. Customer Preference
 - 4. Established Suppliers
 - 5. Emerging Suppliers
 - 6. Major Types of Distributors
 - 7. Market Segmentation Factor

POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges



COMPETITIVE PROFILES

Abbott AdnaGen/Alere **Agilent Technologies** Applied Gene Technologies Arca Biopharma Beckman Coulter/Danaher **Becton Dickinson Biomedical Diagnostics** bioMerieux **Bio-Rad** CellSearch Cepheid Correlogic Systems/Vermillion **Decode Genetics** Diadexus Diagnocure Diasorin **Eiken Chemical** Elitech Group Enterix Enzo Biochem **Epigenomics Exact Sciences** Fujirebio **Guided Therapeutics** Hologic/Gen-Probe Kreatech/Leica Kyowa Medex Mackay Life Sciences Myriad Genetics OncoLab **Otho-Clinical Diagnostics** Panacea Pharmaceuticals **Polartechnics** Polymedco PreMD



Qiagen Quest Diagnostics Radient Pharmaceuticals Roche Scienion Sequenom Siemens Healthcare Takara Bio Targeted Diagnostics & Therapeutics Thermo Fisher Tosoh Veridex Wako Pure Chemicals Wallac/PE Zila/Alere

APPENDIXES

Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications Appendix II: Assumed Currency Exchange Rates



List Of Tables

LIST OF TABLES

Tumor Marker Classification Major Companies Developing or Marketing ACTH Tests Major Companies Developing or Marketing AFP Tests Major Companies Developing or Marketing Beta-2 Microglobulin Tests Major Companies Developing or Marketing CA 15-3/27.29 Tests Major Companies Developing or Marketing CA 19-9 Tests Major Companies Developing or Marketing CA 125 Tests Major Companies Developing or Marketing Calcitonin Tests Major Companies Developing or Marketing CEA Tests Major Companies Developing or Marketing Estrogen Receptor Tests Major Companies Developing or Marketing Progesterone Receptor Tests Major Companies Developing or Marketing Ferritin Tests Major Companies Developing or Marketing Gastrin Tests Major Companies Developing or Marketing HCG Tests Major Companies Developing or Marketing Insulin Tests Major Companies Developing or Marketing NSE Tests Major Companies Developing or Marketing Occult Blood Tests Major Companies Developing or Marketing PAP Smear/HPV Tests Major Companies Developing or Marketing PAP Tests Major Companies Developing or Marketing PSA Tests Major Companies Developing or Marketing Lymphocyte Subclassification Tests **Biochemical Markers Potential Applications In Cancer Diagnosis Oncogenes Potential Applications In Cancer Diagnosis** Major Companies Developing or Marketing Oncogene Tests Growth Factors Potential Applications In Cancer Diagnosis Colony Stimulating Factors Potential Applications in Cancer Diagnosis Lymphokines Potential Applications In Cancer Diagnosis Immunohistochemical Stains Potential Applications in Cancer Diagnosis Executive Summary Table: Italy, Hospital Cancer Diagnostic Test Volume and Sales Forecast Italy, Estimated Cancer Death Rates Per 100,000 Population Italy, Hospital Laboratories Performing Cancer Diagnostic Tests Italy, Hospital Laboratories Performing Cancer Diagnostic Tests by Bed Size Italy, Hospital Laboratories Major Cancer Diagnostic Test Volume Forecast Italy, Hospital Laboratories Major Tumor Marker Forecast by Test



Italy, Total Cancer Diagnostics Sales by Major Supplier Italy, AFP Testing Market Diagnostics Sales by Major Supplier Italy, CEA Testing Market Diagnostics Sales by Major Supplier Italy, PSA Testing Market Diagnostics Sales by Major Supplier



I would like to order

Product name: 2015-2019 Growth Strategies for the Italian Hospital Tumor Marker Testing Market Product link: <u>https://marketpublishers.com/r/293EBA63CD6EN.html</u>

Price: US\$ 3,080.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/293EBA63CD6EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970